Company intelligence / Profile preview

Trutino Biosciences

San Diego, California, United Statestrutinobio.com ↗

Ownership: Private
Development stage: Other

Overview

Lead asset ODC‑IL2/TB‑055 has demonstrated preclinical proof-of-concept with tumor-localized activation of immune response and reduced systemic toxicity. IND approval secured; first-in-human studies planned for late 2024/early 2025.[1][6] No published clinical results yet.

Therapeutic areas: OncologyImmunology
Modalities: Cytokines (engineered/conditional pro-cytokines)Large molecules[6][7][8]Fc-fusion proteins and antibodies mentioned as expertise area[9]
Industry: Biotech

Drug pipeline

7 assets

ODC-IL2

6 more assets in the full pipeline.

Request access →

Partnerships

Boehringer Ingelheim—option-to-acquire agreement and ongoing research partnership focused on immuno-oncology/cytokine therapies.[3]

Beyond the preview

Go deeper on Trutino Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trutino Biosciences.

Explore the full profile